ANNX · Annexon, Inc.

0001193125-26-131782

Summary

Annexon reported deepening GAAP losses and accelerated cash burn in FY2025, reflecting intensified R&D investments in late-stage pipeline advancement including global regulatory submissions and clinical trials, consistent with its pre-revenue biotech trajectory.

Key takeaways

Operating income was -$216.4M, a 40.5% widening versus -$154.1M in FY2024, driven by elevated R&D expenditures.
Net income was -$206.7M, deteriorating 49.6% from -$138.2M last year amid ongoing development focus.
Diluted EPS was $-1.34, down 32.7% from $-1.01, reflecting expanded operating losses.
Net cash from operating activities was -$186.4M, up from -$118.0M prior year due to R&D acceleration.

Full analysis

These results have adversely affected stockholders' equity and working capital, with prior and expected future losses continuing this trend. Operating under pre-revenue biotech realities, Annexon prioritizes pipeline milestones over near-term profitability, positioning for potential catalysts while managing liquidity through focused capital raises and operational efficiencies.